July 2024 – Page 260 – Get News Story

Lichen Planus Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration & Companies by DelveInsight

“Lichen Planus Pipeline”

Lichen Planus companies are Novartis, Amgen, Kiniksa Pharmaceuticals, AFYX Therapeutics, Regeneus, and others.

(Albany, United States) As per DelveInsight’s assessment, globally, Lichen Planus pipeline constitutes 6+ key companies continuously working towards developing 6+ Lichen Planus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Lichen Planus Pipeline Insight, 2024″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Lichen Planus Market.

The Lichen Planus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report here @ Lichen Planus Pipeline Analysis

Some of the key takeaways from the Lichen Planus Pipeline Report:

Lichen Planus Companies across the globe are diligently working toward developing novel Lichen Planus treatment therapies with a considerable amount of success over the years.
Lichen Planus companies working in the treatment market are Novartis, Amgen, Kiniksa Pharmaceuticals, AFYX Therapeutics, Regeneus, and others, are developing therapies for the Lichen Planus treatment.
Emerging Lichen Planus therapies such as Rivelin-CLO, LP-10, and others are expected to have a significant impact on the Lichen Planus market in the coming years.
In February 2024, Stratpharma AG announced results of a VALOR: Vaginal Atrophy & Long-term Observation of Recovery (VALOR)
In April 2024, Koite Health Oy announced results of a Dual-light Antibacterial Photodynamic Therapy as an Adjunctive Treatment to Topical Corticosteroid Treatment in Patients With Gingival Involvement of Oral Lichen Planus – a Randomized Study
In January 2024, Lipella Pharmaceuticals announced results of a Multicenter, Dose-Ranging Trial Evaluating the Safety, Tolerability, and Efficacy of LP-10 in Subjects With Symptomatic Oral Lichen Planus

Lichen Planus Overview

Lichen planus is a chronic inflammatory condition affecting the skin and mucous membranes. It is characterized by itchy, flat-topped, purplish lesions on the skin and white, lacy patches in the mouth. The exact cause of lichen planus is unknown, but it is believed to be an autoimmune disorder where the immune system mistakenly attacks the skin and mucous membrane cells.

On the skin, lichen planus commonly appears on the wrists, ankles, and lower back, presenting as polygonal, purplish, itchy bumps. Oral lichen planus typically affects the inside of the cheeks, gums, and tongue, manifesting as white, lacy patches or painful sores. Other areas that can be affected include the nails, scalp, and genital region.

Lichen Planus Diagnosis is primarily clinical, based on the characteristic appearance of the lesions. A biopsy may be performed to confirm the diagnosis and rule out other conditions.

Lichen Planus Treatment aims to relieve symptoms, as there is no cure for lichen planus. Topical corticosteroids are the first line of treatment to reduce inflammation and itching. Severe cases may require systemic treatments like oral corticosteroids, retinoids, or immunosuppressive drugs. Good oral hygiene and avoiding triggers such as stress and certain medications can help manage the condition.

While lichen planus can be chronic and recurrent, it is generally not life-threatening. Regular follow-up with a healthcare provider is important to monitor and manage the condition effectively.

Get a Free Sample PDF Report to know more about Lichen Planus Pipeline Therapeutic Assessment- Lichen Planus Treatment Market

Lichen Planus Route of Administration

Lichen Planus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical
Molecule Type

Lichen Planus Molecule Type

Lichen Planus Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Lichen Planus Pipeline Therapeutics Assessment

Lichen Planus Assessment by Product Type
Lichen Planus By Stage and Product Type
Lichen Planus Assessment by Route of Administration
Lichen Planus By Stage and Route of Administration
Lichen Planus Assessment by Molecule Type
Lichen Planus by Stage and Molecule Type

DelveInsight’s Lichen Planus Report covers around 6+ products under different phases of clinical development like-

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Lichen Planus product details are provided in the report. Download the Lichen Planus pipeline report to learn more about the emerging Lichen Planus therapies- Lichen Planus Therapeutic Assessment

Lichen Planus Pipeline Analysis:

The Lichen Planus pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Lichen Planus with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lichen Planus Treatment.
Lichen Planus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Lichen Planus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Lichen Planus market.

Download Sample PDF Report to know more about Lichen Planus drugs and therapies- Lichen Planus Clinical Trials and FDA Approvals

Scope of Lichen Planus Pipeline Drug Insight

Coverage: Global
Key Lichen Planus Companies: Novartis, Amgen, Kiniksa Pharmaceuticals, AFYX Therapeutics, Regeneus, and others.
Key Lichen Planus Therapies: Rivelin-CLO, LP-10, and others.
Lichen Planus Therapeutic Assessment: Lichen Planus current marketed and Lichen Planus emerging therapies
Lichen Planus Market Dynamics: Lichen Planus market drivers and Lichen Planus market barriers

Request for Sample PDF Report for Lichen Planus Pipeline Assessment and clinical trials – Lichen Planus Drugs and Therapies

Table of Contents

Lichen Planus Report Introduction
Lichen Planus Executive Summary
Lichen Planus Overview
Lichen Planus- Analytical Perspective In-depth Commercial Assessment
Lichen Planus Pipeline Therapeutics
Lichen Planus Late Stage Products (Phase II/III)
Lichen Planus Mid Stage Products (Phase II)
Lichen Planus Early Stage Products (Phase I)
Lichen Planus Preclinical Stage Products
Lichen Planus Therapeutics Assessment
Lichen Planus Inactive Products
Company-University Collaborations (Licensing/Partnering) Analysis
Lichen Planus Companies
Lichen Planus Key Products
Lichen Planus Unmet Needs
16 . Lichen Planus Market Drivers and Barriers
Lichen Planus Future Perspectives and Conclusion
Lichen Planus Analyst Views
Appendix
About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lichen Planus Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration & Companies by DelveInsight

Celiac Disease Clinical Trials Analysis 2024: FDA Approvals, Therapies, Treatment Market, ROA, MOA and Companies by DelveInsight

“Celiac Disease Pipeline”

Celiac Disease companies are AMYRA Biotech AG, Equillium Bio., Chugai Pharmaceutical Co., Ltd., Calypso Biotech, ImmunogenX, Inc., Amgen Inc., and others.

(Albany, United States) As per DelveInsight’s assessment, globally, Celiac Disease pipeline constitutes 25+ key companies continuously working towards developing 25+ Celiac Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Celiac Disease Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Celiac Disease Market.

The Celiac Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report @ Celiac Disease Pipeline Outlook

Some of the key takeaways from the Celiac Disease Pipeline Report:

Celiac Disease Companies across the globe are diligently working toward developing novel Celiac Disease treatment therapies with a considerable amount of success over the years.
Celiac Disease companies working in the treatment market are AMYRA Biotech AG, Equillium Bio., Chugai Pharmaceutical Co., Ltd., Calypso Biotech, ImmunogenX, Inc., Amgen Inc., and others, are developing therapies for the Celiac Disease treatment

Emerging Celiac Disease therapies in the different phases of clinical trials are- AMY02, EQ102, DONQ52, CALY-002, Latiglutenase, Ordesekimab, and others are expected to have a significant impact on the Celiac Disease market in the coming years.
On March 2024, Takeda announced results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-062 for the Treatment of Active Celiac Disease in Subjects Attempting a Gluten-Free Diet
On March 2024, Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA announced results of a Phase 2a Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of KAN-101 In Participants With Celiac Disease.
On December 2023, Topas Therapeutics GmbH announced results of a Double-blind, Randomized, Placebo-controlled, Phase 2a Study to Evaluate the Safety, Tolerability, and Pharmacodynamic (PD) Effects of Two Infusions of Escalating Doses of TPM502 in Adults Diagnosed With Celiac Disease.
On November 2023, Chugai Pharmaceutical announced results of a Phase I, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Biomarkers of DONQ52 in Celiac Disease Patients (LILY Study).
On September 2023, Regeneron Pharmaceuticals announced results of a study based on T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge.

Celiac Disease Overview

Celiac disease is an autoimmune disorder triggered by the ingestion of gluten—a protein found in wheat, barley, and rye—in genetically predisposed individuals. When someone with celiac disease consumes gluten, their immune system responds by damaging the lining of the small intestine. This damage impairs the absorption of nutrients from food, leading to various symptoms and potential long-term complications.

Symptoms of celiac disease can vary widely and may include gastrointestinal issues like diarrhea, abdominal pain, bloating, and constipation, as well as non-gastrointestinal symptoms such as fatigue, joint pain, skin rashes, and neurological problems.

Celiac disease Diagnosis typically involves blood tests to check for specific antibodies associated with celiac disease, followed by confirmation through a biopsy of the small intestine to assess for characteristic damage to the intestinal lining.

The primary treatment for celiac disease is strict adherence to a gluten-free diet, which involves avoiding all foods containing wheat, barley, and rye. This typically leads to symptom resolution, intestinal healing, and prevention of complications. Additionally, individuals with celiac disease may benefit from nutritional supplementation and regular monitoring by healthcare professionals to ensure optimal management of the condition and prevent potential deficiencies or complications.

Get a Free Sample PDF Report to know more about Celiac Disease Pipeline Therapeutic Assessment – Celiac disease Treatment Market

Emerging Celiac Disease Drugs Under Different Phases of Clinical Development Include:

AMY02 : AMYRA Biotech AG
EQ102 : Equillium Bio.
DONQ52 : Chugai Pharmaceutical Co., Ltd.
CALY-002 : Calypso Biotech
Latiglutenase : ImmunogenX, Inc.
Ordesekimab : Amgen Inc.

Celiac Disease Route of Administration

Celiac Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Molecule Type

Celiac Disease Molecule Type

Celiac Disease Products have been categorized under various Molecule types, such as

Oligonucleotide
Peptide
Small molecule

Celiac Disease Pipeline Therapeutics Assessment

Celiac Disease Assessment by Product Type
Celiac Disease By Stage and Product Type
Celiac Disease Assessment by Route of Administration
Celiac Disease By Stage and Route of Administration
Celiac Disease Assessment by Molecule Type
Celiac Disease by Stage and Molecule Type

DelveInsight’s Celiac Disease Report covers around 25+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Celiac Disease product details are provided in the report. Download the Celiac Disease pipeline report to learn more about the emerging Celiac Disease therapies – Celiac disease Therapeutic Assessment

Some of the key companies in the Celiac Disease Therapeutics Market include:

Key companies developing therapies for Celiac Disease are AMYRA Biotech AG, Equillium Bio., Chugai Pharmaceutical Co., Ltd., Calypso Biotech, ImmunogenX, Inc., Amgen Inc., and others.

Celiac Disease Pipeline Analysis:

The Celiac Disease pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Celiac Disease with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Celiac Disease Treatment.
Celiac Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Celiac Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Celiac Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Celiac Disease drugs and therapies – Celiac disease Clinical Trials and FDA Approvals

Celiac Disease Pipeline Market Drivers

Increasing prevalence of Celiac Disease, increasing R&D activities, no Approved Therapy are some of the important factors that are fueling the Celiac Disease Market.

Celiac Disease Pipeline Market Barriers

However, limited patient awareness about the disease, poor Patient Compliance and other factors are creating obstacles in the Celiac Disease Market growth.

Scope of Celiac Disease Pipeline Drug Insight

Coverage: Global
Key Celiac Disease Companies: AMYRA Biotech AG, Equillium Bio., Chugai Pharmaceutical Co., Ltd., Calypso Biotech, ImmunogenX, Inc., Amgen Inc., and others
Key Celiac Disease Therapies: AMY02, EQ102, DONQ52, CALY-002, Latiglutenase, Ordesekimab, and others
Celiac Disease Therapeutic Assessment: Celiac Disease current marketed and Celiac Disease emerging therapies
Celiac Disease Market Dynamics: Celiac Disease market drivers and Celiac Disease market barriers

Request for Sample PDF Report for Celiac Disease Pipeline Assessment and clinical trials – Celiac disease Therapies and Drugs

Table of Contents

1. Celiac Disease Report Introduction

2. Celiac Disease Executive Summary

3. Celiac Disease Overview

4. Celiac Disease- Analytical Perspective In-depth Commercial Assessment

5. Celiac Disease Pipeline Therapeutics

6. Celiac Disease Late Stage Products (Phase II/III)

7. Celiac Disease Mid Stage Products (Phase II)

8. Celiac Disease Early Stage Products (Phase I)

9. Celiac Disease Preclinical Stage Products

10. Celiac Disease Therapeutics Assessment

11. Celiac Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Celiac Disease Key Companies

14. Celiac Disease Key Products

15. Celiac Disease Unmet Needs

16 . Celiac Disease Market Drivers and Barriers

17. Celiac Disease Future Perspectives and Conclusion

18. Celiac Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Celiac Disease Clinical Trials Analysis 2024: FDA Approvals, Therapies, Treatment Market, ROA, MOA and Companies by DelveInsight

Type 1 Diabetes Treatment Market 2032: Clinical Trials, FDA Approvals, Therapies, Prevalence, Companies by DelveInsight

“Type 1 Diabetes Treatment Market”

Type 1 Diabetes Companies are Landos Biopharma, Zealand Pharma, Prevention Bio, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Novartis, ImCyse, , Tolerion, Avotres, REMD Biotherapeutics, Novo Nordisk, Eledon Pharmaceuticals, Avotres, Eli Lilly, GEROPHARM, Regeneron Pharmaceuticals, Novartis, ViaCyte, Op-T LLC, Dompe Farmaceutici, ILTOO Pharma, Throne Biotechnologies, Oramed, Adocia, Imcyse, Janssen Biotech, Xeris Pharmaceuticals, Zealand Pharma, Jaguar Gene Therapy, more.

(Albany, USA) DelveInsight’s “Type 1 Diabetes Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Type 1 Diabetes, historical and forecasted epidemiology as well as the Type 1 Diabetes market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Type 1 Diabetes market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Type 1 Diabetes market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Type 1 Diabetes treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Type 1 Diabetes market.

Request for a Free Sample Report @ Type 1 Diabetes Market Forecast

Some facts of the Type 1 Diabetes Market Report are:

According to DelveInsight, Type 1 Diabetes market size is expected to grow at a decent CAGR by 2032.
Leading Type 1 Diabetes companies working in the market are Landos Biopharma, Zealand Pharma, Prevention Bio, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Novartis, ImCyse, , Tolerion, Avotres, REMD Biotherapeutics, Novo Nordisk, Eledon Pharmaceuticals, Avotres, Eli Lilly and Company, GEROPHARM, Regeneron Pharmaceuticals, Diamyd Medical, NextCell Pharma, Novartis, ViaCyte, Op-T LLC, Dompe Farmaceutici, ILTOO Pharma, Throne Biotechnologies, Oramed, Adocia, Imcyse, Janssen Biotech, Xeris Pharmaceuticals, Zealand Pharma, Jaguar Gene Therapy, SQZ Biotech, Enthera, and others.
Key Type 1 Diabetes Therapies expected to launch in the market are LABP 111, TTP 399, Teplizumab, Emricasan, VX 880, Encapsulated islet cell program, Eflornithine oral, Iscalimab, IMCY 0098, AT-1501, TOL 3021, AVT001, Volagidemab, NNC0363 0845, NNC0268-0965, LY 3209590, GP40071, Autoimmune diabetes vaccine, ProTrans, MHS 552, VC-02, OPT101, VC-01, Ladarixin, Aldesleukin, Stem Cell Educator therapy, ORMD-0801, ADO09, IMCY-0098, Glucagon intranasal, Golimumab, LY 900027, PRAM9JAG301, Dasiglucagon, SQZ TAC research program, Ent001, and others.
In March 2024, Novo Nordisk received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), endorsing the marketing authorization for AWIQLI (once-weekly basal insulin icodec) for treating diabetes in adults.
In March 2023, Sanofi announced acquisition of Provention Bio, which includes adding TZIELD to its portfolio. TZIELD is recognized as the first disease-modifying treatment designed to delay Stage 3 type 1 diabetes (T1D).

Type 1 Diabetes Overview

Type 1 diabetes is a chronic autoimmune condition where the immune system attacks and destroys insulin-producing beta cells in the pancreas. Insulin is crucial for regulating blood sugar (glucose) levels by facilitating its absorption into cells for energy. Without enough insulin, glucose accumulates in the bloodstream, leading to high blood sugar levels, which can cause various complications over time.

This condition typically develops during childhood or adolescence but can occur at any age. Its exact cause is unknown, but genetics and environmental factors play significant roles. Symptoms include frequent urination, increased thirst and hunger, weight loss, fatigue, and blurred vision.

Management of type 1 diabetes involves daily insulin injections or infusion via a pump, along with monitoring blood sugar levels, following a healthy diet, regular exercise, and careful management of other health conditions. Although there is currently no cure for type 1 diabetes, proper treatment and lifestyle adjustments can help individuals lead fulfilling lives while reducing the risk of complications.

Learn more about Type 1 Diabetes treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Type 1 Diabetes Treatment Market

Type 1 Diabetes Market

The Type 1 Diabetes market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Type 1 Diabetes market trends by analyzing the impact of current Type 1 Diabetes therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Type 1 Diabetes market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Type 1 Diabetes market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Type 1 Diabetes market in 7MM is expected to witness a major change in the study period 2019-2032.

Type 1 Diabetes Epidemiology

The Type 1 Diabetes epidemiology section provides insights into the historical and current Type 1 Diabetes patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Type 1 Diabetes market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Type 1 Diabetes Epidemiology @ Type 1 Diabetes Prevalence

Type 1 Diabetes Drugs Uptake

This section focuses on the uptake rate of the potential Type 1 Diabetes drugs recently launched in the Type 1 Diabetes market or expected to be launched in 2019-2032. The analysis covers the Type 1 Diabetes market uptake by drugs, patient uptake by therapies, and sales of each drug.

Type 1 Diabetes Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Type 1 Diabetes market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Type 1 Diabetes Pipeline Development Activities

The Type 1 Diabetes report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Type 1 Diabetes key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Type 1 Diabetes pipeline development activities @ Type 1 Diabetes Clinical Trials and FDA Approvals

Type 1 Diabetes Therapeutics Assessment

Major key companies are working proactively in the Type 1 Diabetes Therapeutics market to develop novel therapies which will drive the Type 1 Diabetes treatment markets in the upcoming years are Landos Biopharma, Zealand Pharma, Prevention Bio, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Novartis, ImCyse, , Tolerion, Avotres, REMD Biotherapeutics, Novo Nordisk, Eledon Pharmaceuticals, Avotres, Eli Lilly and Company, GEROPHARM, Regeneron Pharmaceuticals, Diamyd Medical, NextCell Pharma, Novartis, ViaCyte, Op-T LLC, Dompe Farmaceutici, ILTOO Pharma, Throne Biotechnologies, Oramed, Adocia, Imcyse, Janssen Biotech, Xeris Pharmaceuticals, Zealand Pharma, Jaguar Gene Therapy, SQZ Biotech, Enthera, and others.

Learn more about the emerging Type 1 Diabetes therapies & key companies @ Type 1 Diabetes Drugs Market

Type 1 Diabetes Report Key Insights

1. Type 1 Diabetes Patient Population

2. Type 1 Diabetes Market Size and Trends

3. Key Cross Competition in the Type 1 Diabetes Market

4. Type 1 Diabetes Market Dynamics (Key Drivers and Barriers)

5. Type 1 Diabetes Market Opportunities

6. Type 1 Diabetes Therapeutic Approaches

7. Type 1 Diabetes Pipeline Analysis

8. Type 1 Diabetes Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Type 1 Diabetes Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Type 1 Diabetes Competitive Intelligence Analysis

4. Type 1 Diabetes Market Overview at a Glance

5. Type 1 Diabetes Disease Background and Overview

6. Type 1 Diabetes Patient Journey

7. Type 1 Diabetes Epidemiology and Patient Population

8. Type 1 Diabetes Treatment Algorithm, Current Treatment, and Medical Practices

9. Type 1 Diabetes Unmet Needs

10. Key Endpoints of Type 1 Diabetes Treatment

11. Type 1 Diabetes Marketed Products

12. Type 1 Diabetes Emerging Therapies

13. Type 1 Diabetes Seven Major Market Analysis

14. Attribute Analysis

15. Type 1 Diabetes Market Outlook (7 major markets)

16. Type 1 Diabetes Access and Reimbursement Overview

17. KOL Views on the Type 1 Diabetes Market

18. Type 1 Diabetes Market Drivers

19. Type 1 Diabetes Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Type 1 Diabetes Treatment Market 2032: Clinical Trials, FDA Approvals, Therapies, Prevalence, Companies by DelveInsight

Premium Springless Carabiner: Fusing Modern Materials with Traditional Craftsmanship

“Nishinaga Industry Co., Ltd. and Monotsuku Industry Co., Ltd. have launched a springless carabiner in the U.S. market. Available in carbon fiber, brass, and steel, this carabiner combines durability and ease of use. Crafted by Japanese artisans, it is ideal for everyday and outdoor use. The Kickstarter crowdfunding campaign is now live.”

An innovative springless carabiner crafted with Japanese artisanal skill, offering durability and ease of use for both outdoor adventures and everyday life.

Nishinaga Industries Co., Ltd., located in Matsuyama City, Ehime Prefecture, Japan, in collaboration with Monotsuku Industries Co., Ltd., has developed a new style of carabiner. We are pleased to introduce three variants — ‘Carbon Fiber,’ ‘Brass,’ and ‘Steel’ — to the American market. Designed without the traditional spring, this carabiner offers exceptional durability and ease of use, making it perfect for both everyday use and outdoor activities.

The Appeal of Springless Design

This carabiner, designed without a spring, is easy to attach and detach, and boasts durability for long-term use. Reflecting user feedback, it is designed to be robust and user-friendly, prioritizing user comfort and product longevity.

Versatile for Everyday Use and Outdoor Activities

The simple yet practical design seamlessly integrates into everyday life while providing excellent functionality in any situation. Its easy one-hand operation allows for stress-free use, even when carrying heavy loads.

High-Quality Craftsmanship by Artisans

From material selection to processing, this carabiner is crafted entirely by Japanese artisans, resulting in a luxurious finish that improves with use over time.

Especially, the brass carabiner develops a unique patina with use, making it a pleasure to use and cherish for a long time.

Use of Cutting-Edge Materials

By utilizing carbon fiber, a material also used in aircraft, rockets, and satellites, we have created a lightweight and highly durable carabiner.

Additionally, the steel carabiner features a unique dull sheen and exceptional durability.

Product Specifications

• Materials: Carbon Fiber, Brass, Steel

• Size: 87×45×4.5mm

• Weight: 11g (Carbon Fiber), 46g (Brass), 44g (Steel)

• Load Capacity: Up to 5kg

Note: This product is not intended for climbing. Please use it as an accessory only.

Monotsuku Industries Co., Ltd. is launching a crowdfunding campaign on Kickstarter starting June 2024, attracting attention from backers and supporters. Stay tuned for further developments.

https://www.kickstarter.com/projects/monozk/edc-revolution-beauty-and-function-in-springless-carabiners

Bringing Japanese Technology to the World

Japan is a treasure trove of advanced technology and traditional craftsmanship. However, many companies are limited to the domestic market, and their superior technology is not well known globally. At Monotsuku Industries, we aim to deliver products that fuse Japanese artisanal skills and new materials to consumers worldwide.This carabiner is a product of the passion and high technical skills of our craftsmen. We hope that people in the United States will try this proud Japanese product and experience its excellence.

Media Contact
Company Name: InterDD,LLC
Contact Person: Takami Sueyoshi
Email: Send Email
Phone: 720-412-1250
Address:1001 Wolf Creek Dr.
City: Longmont
State: Colorado
Country: United States
Website: https://www.kickstarter.com/projects/monozk/edc-revolution-beauty-and-function-in-springless-carabiners

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Premium Springless Carabiner: Fusing Modern Materials with Traditional Craftsmanship

SMX Launches Tech Solution to Enable Centralized Data-Driven Reporting For EUDR Compliance in the Natural Rubber Industry

New York, July 3, 2024 – SMX (Security Matters) PLC (NASDAQ: SMX; SMXWW), a pioneer in digitizing physical objects for a circular economy, proudly announces their new solution to deliver a centralized blockchain reporting system for supply chain data, focusing on ethical sourcing, origination, and brand authentication in the Natural Rubber industry.

SMX technology addresses the challenges faced by multinational organizations in meeting compliance and reporting standards related to:

Ethical sourcing of materials
Child labour
Use of conflict minerals
Use of chemicals & pesticides
Location and identification of farms and farmers
EU Deforestation Regulation (EUDR) reporting

The key benefits include the ability to move marked commodities downstream in a traceable, transparent, and compliant manner, linked to an irrefutable digital blockchain record. This transition from paper-based and manual auditing to real-time digital reporting helps reduce compliance and audit costs, lower reputational risks, and enhance productivity across supply chain operations.

Integrated Supply Chain Monitoring Platform

The Company developed a comprehensive platform for natural rubber producers and suppliers to monitor their supply chains in real-time. This digital platform is designed to integrate data from various sources, including polygon information, satellite imagery, on-ground sensors, risk assessment document management and blockchain records, to provide a holistic view of supply chain activities from tree to finished product in one centralised platform (tree, producer, compounder, manufacturer, brand and recycler).

Customizable Compliance Dashboard

The dashboard is designed to provide real-time updates, alerts, and comprehensive reports for internal and external stakeholders to support the EUDR due diligence statements and reporting requirements at the shipment level. The dashboard will project information from the SMX blockchain and all validated 3rd party data to ensure the highest levels of data integrity. Furthermore the platform would capture the latest deforestation and forest degradation reporting and ties it to the physical movement of natural rubber from tree to finished product. All connections to 3rd party systems are linked via SMX API integration, aiding secure and low cost information sharing.

EU Deforestation Regulation (EUDR) Compliance

The UN Food and Agriculture Organization (FAO) estimates that 420 million hectares of forest were lost to deforestation between 1990 and 2020, with EU consumption representing around 10% of global deforestation. In December 2022, the European Parliament and the Council agreed on an EU regulation to ensure that key goods placed on the EU market will no longer contribute to deforestation and forest degradation.

Once the new rules are enforced, all relevant companies must conduct strict due diligence if they place on the EU market, or export from it, commodities like palm oil, cattle, soy, coffee, cocoa, timber, and rubber. These commodities are major drivers of deforestation due to agricultural expansion. SMX’s tech solution is designed to empower organizations to deliver transparent, auditable, and compliant solutions to meet these EU regulations.

SMX Technology Advantages

SMX technology provides a comprehensive solution that ensures:

Traceability spanning the entire ecosystem of the marked material from origin to final product – without altering the commodities’ original characteristics.
Location-based reporting on material and quality
Adherence to industry best practices
Transparent reporting throughout the supply chain
Regulatory & compliance reporting on supply chains and products from origin to final product sale through a secure digital platform
Enabling near real-time EUDR reporting with information held on the blockchain, satisfying the minimum five-year document storage required by EUDR regulations

Addressing the Complex Supply Chain of Natural Rubber

It has been reported that the natural rubber consumed in the EU is mostly imported with a significant amount produced by small holders. SMX believes that this makes ensuring transparency and traceability extremely challenging. Unsustainable rubber production can lead to deforestation, biodiversity loss, and adverse impacts on smallholders’ living conditions, local communities, and workers’ rights.

SMX believes that the inclusion of natural rubber in the EU Deforestation Regulation will benefit companies with transparent supply chains, such as those that use SMX’s solutions. The new regulation sets strong mandatory due diligence rules for companies that place relevant products on the EU market or export them, ensuring deforestation-free and legal production.

SMX “Plantation to Market” Technology Platform

The integration of SMX technology in the natural rubber supply chain is expected to enable end-to-end traceability and transparent output in terms of Chain of Custody from downstream sources to finished goods sales. Brands will be able to tangibly authenticate and provide irrefutable proof of quality, quantity, and origin, including ethical sourcing and sustainable farming practices, for credible ESG reporting to stakeholders, customers, auditors, and regulators.

SMX technology can address the challenge of ESG criteria, ethical sourcing, and EU deforestation compliance, allowing for digitizing the supply chain in the “first mile” and enabling the movement of natural rubber downstream along with a digital record. The SMX marker can scan and report on the origin location where it was added and first scanned, allowing companies to report in near real-time on all aspects of natural rubber products at any stage of the supply chain

Recent News:

April 10, 2024

SMX Announces Full Industrial Marking Process For Natural Rubber For Vehicle & Truck Tires

NEW YORK, April 10, 2024 SMX (Security Matters) PLC (NASDAQ:SMX; SMXWW), a pioneer in digitizing physical objects for a circular economy, has announced today that it has now successfully completed the marking of 21 tons of natural rubber sourced in Latin America from tree to tire. The program covered the marking at the tree in Latin America through manufacturing and production in the region.

https://www.prnewswire.com/news-releases/smx-announces-full-industrial-marking-process-for-natural-rubber-for-vehicle–truck-tires-302112996.html

Invisible Markers in Tires Ensure Greater Transparency in the Natural Rubber Supply Chain

Continental and SMX (Security Matters) Public Limited Company (NASDAQ: SMX) (NASDAQ: SMXWW), have succeeded for the first time in verifying a marker substance for natural rubber in a tire and so throughout the entire production process.

https://www.prnewswire.com/news-releases/invisible-markers-in-tires-ensure-greater-transparency-in-the-natural-rubber-supply-chain-301770113.html

March 13, 2023

SMX Continental break through deal ensures ethical sourcing and sustainability in rubber tyre supply chain

Security Matters’ (ASX:SMX) and global automotive giant Continental have, for the first time, successfully created a marker substance for natural rubber in a tyres ensuring ethical sourcing and sustainability throughout the entire production process.

Stockhead

https://stockhead.com.au/tech/smx-continental-break-through-deal-ensures-ethical-sourcing-and-sustainability-in-rubber-tyre-supply-chain/

The Australian

https://www.theaustralian.com.au/business/stockhead/smx-continental-deal-ensures-ethical-sourcing-sustainability-in-rubber-tyre-supply-chain/news-story/64594307812c8747632679a1f805b197

Invisible Markers in Tires Ensure Greater Transparency in the Natural Rubber Supply Chain

Continental and Security Matters (SMX), an innovative tech platform specializing in digital tracking using unalterable chemical-based barcodes, have succeeded for the first time in verifying beyond doubt a marker substance for natural rubber in a tire.

https://www.continental.com/en/press/press-releases/20221207-security-matters-smx/

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

For further information contact:

email@securitymattersltd.com

Social XChannels: @smx.tec, @secmattersltd

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

Media Contact
Company Name: Hawk Point Media
Contact Person: Editorial Dept.
Email: info@hawkpointmedia.com
Country: United States
Website: https://hawkpointmedia.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: SMX Launches Tech Solution to Enable Centralized Data-Driven Reporting For EUDR Compliance in the Natural Rubber Industry

Air Changes Heating & Cooling LLC Explains the Benefits of Upgrading to Smart HVAC Systems in Commercial Buildings

Air Changes Heating & Cooling LLC is a leading HVAC service company. In a recent update, the company explained the benefits of upgrading to smart HVAC systems in commercial buildings.

Philadelphia, PA – In a website post, Air Changes Heating & Cooling LLC explained the benefits of upgrading to smart HVAC systems in commercial buildings.

The contractors said that smart HVAC Philadelphia systems offer businesses significant advantages, starting with enhanced energy efficiency. These systems intelligently adjust temperature settings based on occupancy and environmental conditions, optimizing energy consumption and lowering operational costs. By reducing energy waste, businesses can redirect savings towards other critical operational expenses, fostering a more sustainable and cost-effective business environment.

The professionals asserted that smart Philadelphia HVAC systems contribute to improved comfort and productivity within commercial spaces. Through advanced sensors and real-time data analytics, these systems ensure consistent indoor temperature regulation and air quality management. Employees benefit from a more comfortable working environment, which has been shown to boost morale and enhance overall productivity.

The technicians affirmed that the deployment of a smart HVAC system Philadelphia enhances operational transparency and control for facility managers. Remote monitoring capabilities enable real-time performance tracking and proactive maintenance scheduling. By promptly identifying potential issues and addressing them before they escalate, facility managers can optimize system reliability and longevity. This proactive approach extends the lifespan of HVAC equipment and reduces the frequency and urgency of service calls, freeing up resources to focus on core business activities.

About Air Changes Heating & Cooling LLC

Air Changes Heating & Cooling LLC is a premier HVAC service company. The firm specializes in providing comprehensive HVAC solutions tailored to suit the requirements of commercial and residential customers. The crew offers various services, including installation and repair of air conditioning systems. Air Changes Heating & Cooling LLC ensures reliable and efficient HVAC operations that optimize comfort and energy efficiency.

Media Contact
Company Name: Air Changes Heating & Cooling LLC
Contact Person: Jared Pawlowsky
Email: Send Email
Phone: (215) 852-0800
Address:614 Tyson Ave. 1st flr
City: Philadelphia
State: PA
Country: United States
Website: https://www.airchangeshvac.com/

Columbus Roofing Company Highlights Common Roof Types for Homeowners

Columbus Roofing Company is a top-rated roofing company. In a recent update, the company highlighted common roof types for homeowners.

Dublin, OH – In a website post, Columbus Roofing Company highlighted common roof types for homeowners.

The technicians said that asphalt Shingle Roofing in Dublin remains the most widely utilized and cost-effective option. Offering various styles and colors, asphalt shingles seamlessly integrate with various architectural designs. Their affordability and relative ease of installation make them an attractive choice for many homeowners. However, asphalt shingles boast a shorter lifespan than other materials and may underperform in extreme weather conditions.

The experts asserted that metal roofing in Dublin, lauded for its exceptional durability and extended lifespan, stands strong against powerful winds, hail, and even fire. Available in various styles, including panels, shingles, and standing seam, metal roofs effectively reflect sunlight, thereby reducing energy costs in hot climates. While metal roofs offer a sleek, modern aesthetic, their initial investment may be higher than asphalt shingles. Additionally, metal roofs can generate noise during heavy rain or hail.

The professionals mentioned that TPO (Thermoplastic Olefinic Elastomer) is a single-ply membrane roofing system commonly employed on flat or low-slope roofs. TPO roofing in Dublin boasts a lightweight design that facilitates installation and reflects UV rays, contributing to reduced energy costs. It also demonstrates resistance to punctures, tears, and chemicals. However, TPO roofs generally have a shorter lifespan than metal roofs and necessitate professional installation for optimal performance.

About Columbus Roofing Company

Columbus Roofing Company is a premier roofing company. The firm boasts a crew of highly skilled and certified roofers who possess a deep understanding of various roofing systems and materials. They continuously invest in ongoing education and training, ensuring they keep up with the latest developments and best practices in the field. This dedication to knowledge and expertise allows them to deliver unparalleled service and ensure the longevity and integrity of every roof they install.

Media Contact
Company Name: Columbus Roofing Company
Contact Person: Michael McGovern
Email: Send Email
Phone: (614) 245-5213
Address:5131 Post Rd #355
City: Dublin
State: OH
Country: United States
Website: http://columbusroofingco.com/

Rosenbaum & Associates: Leading Brain Injury and Back Hurt Lawyers in Los Angeles

Rosenbaum & Associates, renowned for its unparalleled legal expertise and dedicated client advocacy, announces its continued commitment to serving victims of brain injuries and back injuries in Los Angeles. With over 30 years of experience, the firm’s team of seasoned personal injury attorneys ensures that each client receives the justice and compensation they deserve. More information can be found at https://brainlawsuit.com.

Expertise in Brain Injury Cases

Rosenbaum & Associates understands the devastating impact that brain injuries can have on victims and their families. As leading brain injury lawyers in Los Angeles, the firm has successfully represented clients who have suffered from traumatic brain injuries due to accidents, assaults, and negligence. The firm is dedicated to providing compassionate and comprehensive legal support, ensuring that clients receive the necessary medical care, rehabilitation, and financial compensation.

“Our mission is to fight for the rights of those who have been severely affected by brain injuries,” said Paul Rosenbaum, lead attorney at Rosenbaum & Associates. “We leverage our extensive experience and resources to secure maximum compensation for our clients, helping them rebuild their lives.”

Specialized Back Hurt Legal Services

In addition to its expertise in brain injury cases, Rosenbaum & Associates is also a trusted name for victims seeking a back hurt lawyer. Back injuries, whether from car accidents, workplace incidents, or slips and falls, can lead to chronic pain and long-term disability. The dedicated team works tirelessly to hold negligent parties accountable and secure compensation for medical expenses, lost wages, and pain and suffering.

“We recognize the challenges that come with back injuries,” Rosenbaum stated. “Our goal is to provide robust legal representation to ensure our clients’ rights are protected and their needs are met.”

Notable Case Results

Rosenbaum & Associates’ proven track record speaks volumes about its dedication and success in personal injury litigation. Some of the firm’s notable case results include:

$6,000,000 awarded to a man left with a permanent brain injury after being assaulted by a bouncer.
$75,000 awarded to a child struck by a car while riding his bike.
$8,250,000 awarded to a man left with a permanent brain injury after being assaulted by a bouncer.
$23,500,000 awarded to a man left with a permanent brain injury after being assaulted by a bouncer.

These substantial verdicts and settlements highlight the firm’s commitment to achieving justice for its clients.

Comprehensive Legal Services

Rosenbaum & Associates offers a wide range of personal injury legal services, including but not limited to:

Car Accidents
Bicycle Accidents
Bus Accidents
Motorcycle Accidents
Pedestrian Accidents
Truck Accidents
Uber Accidents
Workplace Injuries
Dog Bites
Traumatic Brain Injuries
Paralysis Injuries
Acid and Chemical Burn Injuries

The firm’s personalized approach ensures that each client receives the attention and expertise needed to navigate the complexities of their case.

Why Choose Rosenbaum & Associates?

Choosing the right legal representation can make a significant difference in the outcome of a case. Here’s why Rosenbaum & Associates stands out:

Experience: Over 30 years of experience in personal injury law.
Dedication: A client-first approach with personalized legal strategies.
Results: A proven track record of securing substantial verdicts and settlements.
Resources: Access to top medical experts and investigative resources.

Get in Touch

If you or a loved one has suffered a brain injury or back injury, don’t hesitate to reach out to the experienced attorneys at Rosenbaum & Associates. The firm is committed to providing the highest level of legal representation to ensure clients receive the compensation they deserve.

Contact Rosenbaum & Associates today at (866) 695-1320 or visit the website at brainlawsuit.com to schedule a free consultation.

About Rosenbaum & Associates

Rosenbaum & Associates is a leading personal injury law firm in Los Angeles, dedicated to providing quick, efficient, and cost-effective legal representation. With over 30 years of experience, the team of skilled attorneys specializes in brain injuries, back injuries, and a wide range of personal injury cases, ensuring clients receive the justice and compensation they deserve.

Media Contact
Company Name: Rosenbaum & Associates
Email: Send Email
City: Los Angeles
State: California
Country: United States
Website: https://brainlawsuit.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Rosenbaum & Associates: Leading Brain Injury and Back Hurt Lawyers in Los Angeles

Nassini Foundation Launches to Empower Women and Children in West Africa

US-based non-profit organization announces initial successes in promoting education, health, and economic opportunities in Togo.

The Nassini Foundation, a US-based non-profit organization dedicated to improving the lives of women and children in West Africa, proudly announces its launch and early successes. Founded to honor the legacy of Tchaisso Gado Nassini, a notable entrepreneur in Togo and China, the foundation focuses on providing access to education, maternal health services, economic opportunities, and protection from gender-based violence, particularly in Togo.

Promoting Access to Education and Health

The Nassini Foundation aims to empower women and children by promoting access to quality healthcare and education. Recognizing the critical need for maternal and pediatric health services in rural and underserved areas, the foundation has initiated the construction of health infrastructure. These centers are equipped to provide comprehensive care to pregnant women, mothers, and children, ensuring that even the most vulnerable populations have access to essential health services.

“We are committed to building and supporting maternal and pediatric health centers that provide quality care to those in need,” said Mia Nassini, founder of the Nassini Foundation. “Our goal is to ensure equitable access to healthcare for women and children in Togo.”

Training and Empowering Health Professionals

The foundation is also focused on the specialized training of health professionals. By strengthening obstetrics, neonatology, and pediatrics skills, the Nassini Foundation aims to improve patient care and outcomes. Training programs are designed to equip health professionals with the knowledge and skills needed to deliver competent and adapted care in maternal and pediatric health infrastructures.

“Every well drilled and training session conducted honors Mr. Tchaisso Gado Nassini’s legacy,” said Nelson Ezi, project manager and a researcher of the foundation. “His vision for a better Togo is reflected in our efforts to build a healthier and more educated community.”

Ensuring Access to Clean Water and Sanitation

Access to clean water and proper sanitation is a cornerstone of the Nassini Foundation’s health initiatives. The organization is implementing drinking water supply and sanitation systems within health infrastructures to ensure a hygienic environment. Additionally, awareness campaigns on hygiene and sanitation are being conducted to prevent diseases and promote maternal and child health.

Advocating for Women’s Rights and Economic Empowerment

The Nassini Foundation is deeply committed to promoting women’s rights and economic empowerment. Efforts are underway to raise awareness about women’s rights in reproductive health and access to healthcare. The foundation facilitates women’s access to reproductive health services, including family planning and screening services, ensuring that women can make informed decisions about their own health.

The Nassini Foundation is implementing economic empowerment programs to further support women’s financial independence. These programs include vocational training, access to micro-credit, and support for entrepreneurship. By encouraging women’s involvement in income-generating activities, the Nassini Foundation aims to strengthen their financial autonomy.

Responding to Emergencies with Agility and Sensitivity

The Nassini Foundation is also responsive to life-threatening emergencies where its involvement is needed and appropriate. With a foundation of experience and sensitivity to situational requirements, the organization is willing to take intelligent risks and act quickly to address urgent needs.

“We are members of an international partnership that transcends legal, structural, and cultural boundaries,” Mia Nassini explained. “We accept the obligations of joint participation, shared goals, and mutual accountability that true partnership requires.”

The Nassini Foundation’s early successes highlight its commitment to improving the lives of women and children in West Africa. As the organization continues to grow, it remains dedicated to its mission of promoting education, health, and economic opportunities, creating a brighter future for the communities it serves.

For more information about the Nassini Foundation and its initiatives, please visit https://nassinifoundation.org or follow them on Instagram at @nassini_foundation_.

About the Nassini Foundation

The Nassini Foundation is a registered 501(c)3 charity organization based in the United States. Dedicated to alleviating the suffering of underprivileged women and children in West Africa, the foundation focuses on providing access to quality healthcare, education, economic opportunities, and protection from gender-based violence. Founded in honor of Tchaisso Gado Nassini, the foundation continues his legacy of empowering communities and fostering sustainable development.

Media Contact
Company Name: Nassini Foundation
Contact Person: Mia Nassini
Email: Send Email
Phone: +1 (610) 989 2838
Country: United States
Website: https://nassinifoundation.org

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Nassini Foundation Launches to Empower Women and Children in West Africa

LiTime to Debut New Electric Outboard Motor LiFePO4 Battery at ICAST, the World’s Largest Sport Fishing Trade Show

From July 16 to 19, the Orange County Convention Center in Orlando will host the 2024 ICAST, the world’s premier sport fishing trade show. This event, often referred to as the “Super Bowl” of the fishing industry, showcases the latest gear and accessories from top brands. Shenzhen-based battery brand LiTime will unveil its latest innovation: the market’s first lithium iron phosphate (LiFePO4) battery designed specifically for electric outboard motors. These new products aim to enhance the fishing experience and will be available for a 15-day online pre-sale starting June 28 on the LiTime website, offering special pre-sale prices.

Innovation in Battery Technology: The First of Its Kind for Electric Outboard Motors

In May 2023, the U.S. Environmental Protection Agency set stringent greenhouse gas emission standards under the Clean Air Act, focusing on the transportation sector and existing gas turbine standards. Electric boats are emerging as the future trend, rapidly replacing fuel-powered vessels. In response to these regulations and market demands, LiTime developed two electric power batteries for boats: the 12V 100Ah OBM battery and the 36V 100Ah OBM battery.

These new batteries are the first specifically designed for marine electric outboard motors. They feature IP65 dust and water resistance, upgraded low-temperature protection, and smart capabilities with Bluetooth 5.0 connectivity via QR code scan, allowing users to check power status easily on their smartphones. The advanced Battery Management System (BMS) provides over 20 types of protection, supports 500A/1S discharge, automatic recovery within 30 seconds after overload, and enhanced resistance to moisture and salt spray.

High Performance: Long-Lasting, Lightweight, Maintenance-Free Batteries

The 12V 100Ah OBM (Outboard Motor) LiFePO4 battery: This battery supports configurations up to 5S5P for a total of 60V 500Ah, specifically designed to meet the high-capacity needs of outboard motors, accommodating 24V, 36V, 48V, and 60V outboard motors. With an energy capacity of 1280Wh, it can manage surge discharge currents up to 500A for 1 second, handling the initial high current during motor startup. It also features a sustained discharge rate of 1.2C for 3 minutes and can automatically recover from overload protection within 30 seconds, eliminating concerns about battery shutdowns.

The 36V 100Ah OBM (Outboard Motor) LiFePO4 battery: This battery supports 4P2S configurations, and two in series can power a 72V electric outboard motor up to 10 horsepower. A single battery is equivalent to three 12V 100Ah lead-acid batteries in series, achieving superior performance with no messy cables, saving space of two lead-acid batteries, reducing weight by 65%, and doubling endurance. It also offers over 4000 deep cycles, exceeding the lifespan of lead-acid batteries by more than five times.

Offline Debut: Introducing New Products Exclusively at ICAST

ICAST, which attracts industry experts and innovative companies globally, provides an ideal platform for LiTime to showcase its cutting-edge lithium iron phosphate battery technology. As a member of the American Boat and Yacht Council (ABYC), LiTime is dedicated to providing safe and reliable marine batteries. The launch of the new electric outboard motor batteries marks a significant step in the brand’s 2024 strategy, aiming to broaden the application of their batteries across various scenarios. By participating in ICAST, LiTime aims to enhance brand visibility, demonstrate its innovation and technological prowess, and gather valuable market feedback from American customers to optimize their products and services. This aligns with their vision of “making new energy products accessible to everyone and achieving energy independence and freedom.”

About LiTime

Based in Shenzhen, China, LiTime has over 15 years of expertise in new energy storage. Focusing on user needs and technological innovation, LiTime offers comprehensive lithium iron phosphate storage batteries. Certified by the American Boat and Yacht Council (ABYC) and the American Sportfishing Association (ASA) , LiTime is committed to reducing the global carbon footprint and transforming the energy landscape.

Media Contact
Company Name: Shenzhen LiTime Technology Co., Ltd
Contact Person: Shafee Chang
Email: Send Email
Country: China
Website: https://www.litime.com/